Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73611143" target="_blank" >RIV/61989592:15110/21:73611143 - isvavai.cz</a>

Result on the web

<a href="https://com-mendeley-prod-publicsharing-pdfstore.s3.eu-west-1.amazonaws.com/" target="_blank" >https://com-mendeley-prod-publicsharing-pdfstore.s3.eu-west-1.amazonaws.com/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2020.029" target="_blank" >10.5507/bp.2020.029</a>

Result language

angličtina

Original language name

Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma

Original language description

Aims. Angiotensin converting enzyme inhibitors (ACEI) have been recently discussed in connection with the medical treatment of chronic subdural haematoma (CSDH). They may improve the treatment results. The objective of our study was to evaluate the impact of ACEI on the development of CSDH. The first question was to assess the impact of ACEI on postoperative CSDH healing. The second was to assess the impact of ACEI on the development of CSDH as such. Patients and Methods. The study recruited patients treated surgically for CSDH at our department in the 2013–2018 period. Based on medical records, we retrospectively evaluated the clinical condition of the patients, their history (mainly pharmacological – the use of ACEI) and the course of treatment focussing on the reoccurrence of disease ne-cessitating further therapeutic interventions. For the purpose of evaluating the impact of ACEI on postoperative CSDH healing, the patients were divided into two groups: those using ACEI and those without this medication. The results were compared. We also compared the prevalence of ACEI use in patients with CSDH with the prevalence of ACEI in the comparable population. The difference of the rates allowed us to evaluate the impact of ACEI on the development of CSDH itself. Results. Of the 217 patients after surgery for CSDH, 79 continued the use of ACEI; the remaining 138 patients did not use this medication. Patients using ACEI after the surgery experienced a recurrence in 24 (30.4%) cases; patients without ACEI in 37 (26.8%) cases. A negligibly higher number of recurrences was recorded in patients with postoperative use of ACEI, but this difference was not statistically significant (P=0.574). Of a total of 230 patients who underwent surgery for CSDH, 81 were using ACEI chronically (35.2%). In the control group of 100 patients, 38 (38.0%) patients used ACEI. The difference was not statistically significant (P=0.629), so it is not possible to assume that ACEIs influence the development of CSDH as such. Conclusion. The initial high hopes for a positive ACEI effect on the healing of CSDH are now waived after the publica-tion of several recent studies. According to our present knowledge, the development of CSDH does not appear to be influenced by ACEI use.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BIOMEDICAL PAPERS-OLOMOUC

ISSN

1213-8118

e-ISSN

—

Volume of the periodical

165

Issue of the periodical within the volume

2

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

4

Pages from-to

175-178

UT code for WoS article

000660244900010

EID of the result in the Scopus database

2-s2.0-85108823131